Acurx Pharmaceuticals, Inc.(ACXP)

Biotechnology · Staten Island, NY

$1.310.00 (0.00%)

Delayed quote: Oct 6, 2026, 1:08 PM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T17:20:25.136Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:20:25.136Z.

Quote observation: 2026-10-06T17:08:30.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 1.31
Unrounded diluted TTM EPS · period ending 2026-06-30: -3.55

FMP input reference: f2d634a7ba4b3af29dc0bd0f7aeccfce6021194a57d8f55324c803ee9ac920cb

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

ACXP PE Ratio Metrics

PE RATIO

N/A

ACXP Competitors' PE Ratio

ACXP

Acurx Pharmaceuticals, Inc.

Current

Market Cap

$5.63M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NVNO

enVVeno Medical Corporation

vs ACXP

Market Cap

$5.96M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CUPR

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

vs ACXP

Market Cap

$5.74M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LUCY

Lucyd, Inc

vs ACXP

Market Cap

$5.82M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SNOA

Sonoma Pharmaceuticals, Inc.

vs ACXP

Market Cap

$5.84M

PE Ratio

N/A

TTM Avg

5.41

3Y Avg

8.45

5Y Avg

9.86

SNGX

Soligenix, Inc.

vs ACXP

Market Cap

$5.36M

PE Ratio

N/A

TTM Avg

56.51

3Y Avg

56.51

5Y Avg

56.51

LNAI

Lunai Bioworks Inc.

vs ACXP

Market Cap

$5.26M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENLV

Enlivex Therapeutics Ltd.

vs ACXP

Market Cap

$6.06M

PE Ratio

0.00

TTM Avg

0.02

3Y Avg

0.02

5Y Avg

0.02

SCNX

Scienture Holdings, Inc.

vs ACXP

Market Cap

$5.92M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PULM

Pulmatrix, Inc.

vs ACXP

Market Cap

$5.26M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Acurx Pharmaceuticals, Inc. (ACXP)	$5.63M	N/A	N/A	N/A	N/A
enVVeno Medical Corporation (NVNO)vs ›	$5.96M	N/A	N/A	N/A	N/A
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs ›	$5.74M	N/A	N/A	N/A	N/A
Lucyd, Inc (LUCY)vs ›	$5.82M	N/A	N/A	N/A	N/A
Sonoma Pharmaceuticals, Inc. (SNOA)vs ›	$5.84M	N/A	5.41	8.45	9.86
Soligenix, Inc. (SNGX)vs ›	$5.36M	N/A	56.51	56.51	56.51
Lunai Bioworks Inc. (LNAI)vs ›	$5.26M	N/A	N/A	N/A	N/A
Enlivex Therapeutics Ltd. (ENLV)vs ›	$6.06M	0.00	0.02	0.02	0.02
Scienture Holdings, Inc. (SCNX)vs ›	$5.92M	N/A	N/A	N/A	N/A
Pulmatrix, Inc. (PULM)vs ›	$5.26M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$1.31

Forward EPS (Est.)

$-1.72

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.

Staten Island, NY

4 employees

www.acurxpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: David Luci

View full financials

NAME

MARKET CAP

PE RATIO

TTM

Acurx Pharmaceuticals, Inc. (ACXP)

$5.63M

N/A

enVVeno Medical Corporation (NVNO)vs ›

$5.96M

N/A

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs ›

$5.74M

N/A

Lucyd, Inc (LUCY)vs ›

$5.82M

N/A

Sonoma Pharmaceuticals, Inc. (SNOA)vs ›

$5.84M

N/A

5.41

8.45

9.86

Soligenix, Inc. (SNGX)vs ›

$5.36M

N/A

56.51

Lunai Bioworks Inc. (LNAI)vs ›

$5.26M

N/A

Enlivex Therapeutics Ltd. (ENLV)vs ›

$6.06M

0.00

0.02

Scienture Holdings, Inc. (SCNX)vs ›

$5.92M

N/A

Pulmatrix, Inc. (PULM)vs ›

$5.26M

N/A

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

ACXP PE Ratio Metrics

ACXP Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics

PE Ratio: N/A

ACXP PE Ratio Metrics

ACXP Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics